Controversies: Stroke Prevention in Chronic Kidney Disease

Area of Science:

• Nephrology
• Neurology
• Cardiovascular Medicine

Background:

• Patients with chronic kidney disease (CKD), especially end-stage kidney disease, face elevated risks of both ischemic and hemorrhagic stroke.
• Uremic factors such as blood pressure variability, vascular calcification, toxins, inflammation, platelet dysfunction, and microbleeds contribute to stroke risk in CKD.
• Evidence for stroke prevention in CKD is limited due to few randomized trials in advanced stages, relying heavily on observational data.

Purpose of the Study:

• To review and discuss the controversial evidence regarding stroke prevention strategies in the CKD population.
• To evaluate the efficacy of blood pressure control, statins, antiplatelet agents, and anticoagulation in preventing stroke among CKD patients.

Main Methods:

• Review of existing literature, focusing on randomized clinical trials and observational cohorts, particularly those including patients with advanced CKD.
• Analysis of real-world data to assess the effectiveness of various stroke prevention interventions.

Main Results:

• Lowering systolic blood pressure below 120 mmHg and statin use did not demonstrate a significant decrease in stroke risk for CKD patients.
• Antiplatelet agents showed no clear benefit for secondary stroke prevention, though aspirin might reduce incident stroke in hypertensive CKD stages 3B-5.
• Observational data suggests apixaban, a factor Xa inhibitor, may offer a better profile than warfarin in dialysis patients with atrial fibrillation, associated with lower stroke risk and bleeding events.

Conclusions:

• Current evidence suggests limited benefit from aggressive blood pressure targets or statins for stroke prevention in CKD.
• Aspirin may have a role in specific CKD subgroups, while apixaban shows promise over warfarin in dialysis patients with atrial fibrillation regarding stroke and bleeding risk.